Real-World Validation of Menin Inhibition in Acute Leukemia

Summary Syndax presented interim real-world evidence from the ROAR study at EHA 2026 showing an 82% overall response rate and 64% CR/CRh rate among heavily pretreated patients with relapsed or refractory NPM1-mutated or KMT2A-rearranged acute leukemia treated with revumenib. The data provide important confirmation that…